Riva Therapeutics
Brion W. Murray, Ph.D., is a prominent figure in oncology research and development, currently serving as President, CSO, and Co-Founder of Riva Therapeutics since May 2022. This innovative company focuses on precision lethal oncology and collaborates with the Broad Institute of Harvard and MIT. Brion also contributes as a Senior Editor for Molecular Cancer Therapeutics and holds faculty status at the Faculty of 1000, having been recognized as the 2018 Faculty Member of the Year. Additional leadership roles include Associate Editor for Frontiers in Pharmacology and Frontiers in Oncology, and previous positions at Lengo Therapeutics, Turning Point Therapeutics, and Pfizer. Brion's academic background includes a Ph.D. in Biochemistry from the University of Maryland and postdoctoral studies at Scripps Research.
This person is not in any teams
Riva Therapeutics
Riva Therapeutics is a precision oncology company focused on creating transformative medicines for cancer patients. We are developing a new generation of small molecule therapeutics by leveraging deep knowledge of genomic dependencies to selectively target essential tumor cell processes beyond DNA damage repair. Our precision lethal therapies have the potential to provide profound clinical activity, be well-tolerated, and substantially improve patient lives. For more info: https://rivatherapeutics.com/